Plastic and reconstructive surgery · 2025
Relapse to Presurgical Condition after Lymphovenous Anastomosis: Analysis of Risk Factors in a Cohort of 90 Patients.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Higueras Carmen, Xarrié Planas Jan, Del Río Maria, Carrasco López Cristian, Blasi Brugué Marc, Hong Joon Pio, Malagón López Paloma
Аннотация
BACKGROUND: Secondary lymphedema in patients with breast cancer is a debilitating condition that adversely affects quality of life. Lymphovenous anastomosis (LVA) has shown promising results, but its long-term effectiveness is a subject of ongoing investigation. This study was performed to evaluate relapse to a presurgical condition and associated risk factors in patients with breast cancer-related lymphedema (BCRL) treated with LVA. This is the first study to analyze lymphedema relapse after LVA, providing valuable insights for managing patient expectations.
METHODS: Between 2018 and 2023, 90 patients who underwent LVA for BCRL were included in this retrospective study. The authors evaluated relapse and potential risk factors, along with changes in limb circumference, subjective improvement, and frequency of infection episodes.
RESULTS: Relapse to the presurgical condition occurred in 11 patients (12.2%), with a mean time to relapse of 27.4 months after surgery. Patients with International Society of Lymphology stage 3 lymphedema (hazard ratio, 9.88; P < 0.05) and a history of infections (hazard ratio, 3.99; P < 0.05) had a higher incidence of relapse. Two out of 3 patients without regular use of preoperative compressive therapy experienced relapse ( P < 0.05). No significant associations were found between relapse and after surgery compression therapy, previous radiotherapy, duration of lymphedema, age, or body mass index.
CONCLUSIONS: The low relapse rate suggests that LVA is an effective long-term treatment for BCRL. However, advanced stage lymphedema and history of infections in the affected limb may influence long-term effectiveness. Further studies are needed to identify additional risk factors for relapse.
METHODS: Between 2018 and 2023, 90 patients who underwent LVA for BCRL were included in this retrospective study. The authors evaluated relapse and potential risk factors, along with changes in limb circumference, subjective improvement, and frequency of infection episodes.
RESULTS: Relapse to the presurgical condition occurred in 11 patients (12.2%), with a mean time to relapse of 27.4 months after surgery. Patients with International Society of Lymphology stage 3 lymphedema (hazard ratio, 9.88; P < 0.05) and a history of infections (hazard ratio, 3.99; P < 0.05) had a higher incidence of relapse. Two out of 3 patients without regular use of preoperative compressive therapy experienced relapse ( P < 0.05). No significant associations were found between relapse and after surgery compression therapy, previous radiotherapy, duration of lymphedema, age, or body mass index.
CONCLUSIONS: The low relapse rate suggests that LVA is an effective long-term treatment for BCRL. However, advanced stage lymphedema and history of infections in the affected limb may influence long-term effectiveness. Further studies are needed to identify additional risk factors for relapse.